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Abstract 
Background 
There is an urgent need for biomarkers for the early detection of ovarian cancer. The purpose of this 
study was to assess whether changes in serum levels of LCAT, SHBG, GRP78, calprotectin and IGFBP2 
are observed prior to clinical presentation and to assess the performance of these markers alone 
and in combination with CA125 for early detection. 
Methods 
This nested case control study used samples from the UKCTOCS trial. The sample set consisted of 
482 serum samples from 49 OC subjects and 31 controls, with serial samples spanning up to seven 
years pre-diagnosis. The set was divided into: (I) a discovery set which included all women with only 
two samples from each woman, the first at < 14 months and the second at > 32 months to diagnosis; 
and (ii) a corroboration set which included all the serial samples from the same women spanning the 
7 year period. LCAT, SHBG, GRP78, calprotectin and IGFBP2 were measured using ELISA. The 
performance of the markers to detect cancers pre-diagnosis was assessed. 
Results 
A combined threshold model IGFBP2 >78.5 ng/mL: LCAT <8.831 µg/mL: CA125 >35 U/mL 
outperformed CA125 alone for the earlier detection of ovarian cancer. The threshold model was able 
to identify the most aggressive Type II cancers. In addition, it increased the lead time by 5-6 months 
and identified 26% of Type I subjects and 13% of Type II subjects that were not identified by CA125 
alone.  
Conclusion 
Combined biomarker panels (IGFBP2, LCAT and CA125) outperformed CA125 up to 3 years pre-
diagnosis, identifying cancers missed by CA125, providing increased diagnostic lead times for Type I 
and Type II OC. The model identified more aggressive Type II cancers, with women crossing the 
threshold dying earlier; indicating that these markers can improve on the sensitivity of CA125 alone 
for the early detection of ovarian cancer. 
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Introduction 
Ovarian cancer has the highest mortality rate of all the gynaecological cancers with an estimated 
15,500 deaths in the USA in 2012 alone (Siegel et al, 2012). This is due to its typically late diagnosis, 
with 5 year survival rates of 5% in those diagnosed at Stage IV. If diagnosed early, at stage I, the 5 
year survival rate rises to >90% (CRUK, 2014). There is an unmet need for diagnostic tests that 
enable earlier diagnosis, which would increase survival. 
OC can be classified into Type I (more indolent tumours lacking mutations in TP53) and Type II 
(aggressive cancers displaying TP53 mutations in >80% of cases) which account for most of the OC 
mortality) (Kurman & Shih, 2010). Serum CA125 is the only biomarker currently used to triage and 
monitor patients (Jacobs & Bast, 1989a), with a threshold of 35 U/mL triggering referral to a 
gynaecological oncologist (Cramer et al, 2011a). However, CA125 elevation is not unique to OC, as it 
is also raised during menstruation, pregnancy and endometriosis; and it is only elevated in 
approximately 50% of early stage cancers (Jacobs & Bast, 1989a). Extended combinations of 
biomarkers should offer higher discriminatory power. A putative panel of biomarkers, identified at 
OC diagnosis, from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer (Cramer et al, 2011a) 
proved unable to detect OC in pre-clinical samples (Zhu et al, 2011), suggesting putative biomarkers 
were elevated at clinical presentation but not present earlier in the natural history of the disease. 
The prospectively collected serum sample set generated during the United Kingdom Collaborative 
Trial of Ovarian Cancer Screening (UKCTOCS) (Menon et al, 2009a; Menon et al, 2008; Menon et al, 
2015) offers the possibility of discovering biomarkers in pre-clinical serum samples. A previous study 
by the authors’ using isobaric tags (iTRAQ) identified 90 proteins differentially expressed between 
OC cases and controls. A second targeted mass spectrometry analysis of twenty of these putative 
biomarkers led to the successful validation of Protein Z as a potential early detection biomarker for 
OC from the UKCTOCS sample set (Russell et al, 2016). Here a further five putative biomarkers 
identified in this previous work: Lecithin–cholesterol acyltransferase (LCAT), Insulin-like growth 
factor-binding protein 2 (IGFBP2), Sex hormone-binding globulin (SHBG), Glucose-Regulated Protein, 
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78kDa (GRP78) and calprotectin (uniprot accession numbers P04180, P18065, P04278, P11021 and 
complexed P05109 and P06702), were investigated for their utility in OC screening. IGFBP2 and 
SHBG are both hormone binding proteins that have previously been implicated in ovarian cancer 
(Baron-Hay et al, 2004; Flyvbjerg et al, 1997; Gharwan et al, 2015; Nolenu & Lokshin, 2012). LCAT 
has previously been shown to be down regulated in breast cancer at diagnosis (Hilal Kiziltunc & 
Askin, 2013). Calprotectin is an antibacterial cytosolic protein found most abundantly in neutrophils 
and upregulation of serum levels occur during inflammation (Striz & Trebichavsky, 2004), it has 
previously been shown to be upregulated in plasma of women with OC (Odegaard et al, 
2008). GRP78 is a glucose regulated protein which controls protective mechanisms during stress, it 
has been shown to be upregulated in malignant breast lesions (Fernandez et al, 2000), and via 
association with STMN1 to promote metastasis in such tumours (Kuang et al, 2016). 
 We therefore sought to investigate the performance of this panel in combination with CA125 for 
early diagnosis of OC and their ability to identify the most aggressive subtypes in a nested case 
control study within UKCTOCS.    
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Materials and Methods 
Serum Samples 
UKCTOCS (International Standard Randomised Controlled Trial, number ISRCTN22488978; 
ClinicalTrials.gov NCT00058032) is a randomised controlled trial of ovarian cancer screening in the 
general population, approved by the UK North West Multicentre Research Ethics Committees (North 
West MREC 00/8/34). Trial design, including eligibility criteria and details of recruitment has been 
described in detail elsewhere (Menon et al, 2009a; Menon et al, 2008; Menon et al, 2015). All 
women provided written informed consent for use of their samples in secondary studies.  The 
current biomarker discovery study was approved by the Joint UCL/UCLH Committees on the Ethics of 
Human Research (Committee A) (Reference No. 05/Q0505/57). Full details of sample acquisition, 
transport and storage, and CA125 quantification in the sample set have been published previously 
(Menon et al, 2009a). 
The serum set investigated here comprised eighty women; 49 women with OC, 30 Type II and 19 
Type I (of which 10 were borderline and as with previous studies were grouped with Type I for 
analysis (Russell et al, 2016; Shih & Kurman, 2004; Wu et al, 2013); 31 control samples were selected 
from women in the study who had no diagnosis of a cancer during follow-up and were matched by 
age, collection centre and collection date to the Type II samples. This set contained all of the invasive 
ovarian cancer samples available that had serial samples spanning less than 14 months to diagnosis 
right through to greater than 32 months and up to 84 months to diagnosis. Multiple serial samples 
were available from these 80 women so the full sample set comprised 482 individual samples 
spanning up to seven years prior to diagnosis (time to diagnosis- tDx).  
The set was divided into: (i) a discovery set, which comprised two samples per woman, one at <14 
months and the other at >32 months tDx and (ii) a corroboration set which comprised the additional 
serial samples from the same women spanning a 7 year period tDx.  
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Serum measurements  
ELISA assays for IGFBP2 and LCAT (Cloud Clone Corp, Wuhan, Hubei, China), SHBG (R&D Systems, 
Abingdon, UK), GRP78 (Enzo Life Sciences, Exeter, UK) and calprotectin (Biolegend, San Diego, USA) 
were performed in duplicate using commercial kits following manufacturers’ instructions.  
The mean coefficients of variance (CV) for duplicate analysis for each assay were: IGFBP2: 8.1%; 
LCAT: 8.4%; SHBG: 7.4%; GRP78: 3.1% and calprotectin: 4.5%. Serum CA125 levels were available as 
previously described (Menon et al, 2009a). 
Statistical analysis 
All analysis was performed using the R environment for statistical analysis. The Mann-Whitney test 
was used to assess significance of differences. The Fisher exact test was used to assess significance 
of categorical data. Correlations were assessed using Pearson’s product moment. Logic-rule based 
threshold models were constructed to investigate the biomarkers discriminatory power (O'Brien et 
al, 2015). Differences in sensitivity between models were assessed with McNemar's test. The areas 
under the curve (AUC) of receiver operating characteristics (ROC) curves were calculated for 
threshold models. Significance of lead time improvement was calculated with a paired t-test.   All 
tests were two tailed and those with p values <0.05 were considered statistically significant. 
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Results 
Study set characteristics 
The base line characteristics of the study participants and tumour characteristics have previously 
been reported (Russell et al, 2016)  and are provided as  supplementary data (Table S1, S2). Subjects 
BMI, current HRT and oral contraceptive pill use were recorded at recruitment, and HRT use and 
smoking recorded in the first follow up questionnaires sent to all participants 3 to 5 years post 
randomisation. None of these factors correlated with OC diagnosis.  
Serum levels of IGFBP2, SHBG, LCAT, GRP78, calprotectin and CA125 in the discovery set 
In the discovery set IGFBP2, SHBG, LCAT, GRP78 and calprotectin were quantified using commercial 
ELISA kits whilst CA125 levels were available from the main UKCTOCS trial database (Menon et al, 
2009a). Protein expression was log transformed and scaled to unit variance allowing direct 
comparison between markers (Figure 1). The expression of these markers at <14 and >32 months to 
diagnosis were analysed separately for Type I and Type II OC cases (to ascertain if the proteins were 
potential subtype specific early detection markers). The results were then combined and analysed to 
ascertain their potential as pan ovarian cancer early detection biomarkers.  
IGFBP2 showed no significant change in the Type I or Type II individual analysis but did show 
upregulation in the pan OC analysis <14 months to diagnosis (P=0.054). SHBG serum levels were 
significantly down regulated in the Type-I (P=0.018) and the pan OC (P=0.033) >32 months to 
diagnosis. Whilst LCAT showed significant down regulation in Type-I (P=0.0044) and pan OC 
(P=0.0096) <14 months to diagnosis. Neither, GRP78 or calprotectin showed significant regulation 
compared to controls. CA125 showed significant upregulation in serum for Type II (P=7.4x10-8) cases 
at < 14 months to diagnosis. In addition, it showed significant upregulation for both Type I < 14 
months (P=0.0013) and > 32 months (P=0.026) and for pan OC < 14 months (P=2.3x10-7) and > 32 
months (P=0.048) in these samples. 
Correlation of biomarker expression with epidemiological factors 
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Correlation of biomarker expression with epidemiological factors was investigated within the 
discovery set. BMI and contraceptive pill use (“Have you ever taken the oral contraceptive pill? – yes 
or no”) assessed at recruitment and age-at-sample were significantly correlated only with SHBG 
(P=0.009, P=0.034, and P=0.043 respectively). HRT use at recruitment (“Are you currently on 
hormone replacement therapy (HRT)? –yes or no”) was correlated with IGFBP2 (P=0.01) and SHBG 
(P=0.03) expression but HRT use at follow up (“Are you currently taking HRT?” –yes or no) showed 
no correlations with expression. Contraceptive pill use at recruitment was correlated with SHBG 
(P=0.034). Smoking assessed at follow up (“Have you ever been a smoker? –yes or no”) was not 
correlated with any biomarker expression.  
Combined analysis of discovery and corroboration set  
IGBP2, LCAT and SHBG were taken forward for further analysis and were quantified in the additional 
samples of the corroboration set. Protein expression was log transformed and scaled to unit 
variance for comparison. As with the discovery set protein expression was analysed separately for 
Type I and Type II OC cases and the results then combined to investigate their potential as pan 
ovarian cancer early detection biomarkers.  
There are two potential applications for biomarker panels in the early detection of ovarian cancer. 
One is their potential use as aids in clinical ‘triage’ for symptomatic/high risk patients. Analysis of the 
biomarker levels from a single blood sample, with no temporal information, at primary care centres 
could be used to ascertain the risk of ovarian cancer. This is investigated in figure 2 where the levels 
of the potential biomarkers are compared to control levels. The second application would be as part 
of a ‘screening’ programme. Here the levels of the potential markers would be followed temporally 
to determine if they indicated early disease initiation and progression, this is outlined in figure 3. 
IGFBP2, SHBG and CA125 levels display differential expression for OC triage 
The levels of IGBP2, LCAT, SHBG and CA125 were compared directly with those of the control 
population in all samples, figure 2. IGFBP2 was significantly upregulated in Type-I (P=0.024) and in 
the pan OC (P=0.045). SHBG was significantly down regulated in Type-I (P=0.012) and Type-II 
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(P=0.012) and in the pan OC (P=0.0035). LCAT displayed no differential expression at this stage of the 
analysis. CA125 was significantly upregulated in Type-I (P=4.1x10-8) and Type-II (P=3.4x10-13) and in 
the pan OC (P=5.7x10-13).  
IGFBP2, SHBG, LCAT and CA125 display differential expression pre-diagnosis for screening 
The levels of all of the biomarkers were compared directly with those of the control population at  
yearly intervals, from diagnosis up to 4 years pre diagnosis after which all time points >4 years tDx 
were grouped together, figure 3. IGFBP2 was significantly upregulated; in Type-I samples at <1 year 
tDx (P=0.0045) and for pan OC at < 1 year tDx (P=0.014). SHBG was significantly down regulated in 
Type-I samples at 2-3 years tDx (P=0.027) and at the same time point in Type II (P=0.042) and in pan 
OC (P=0.012). LCAT showed significant down regulation in OC with respect to controls in Type-I 
samples <1 year tDx (P=0.0012) and upregulation at > 4 years tDx (P=0.019).  
CA125 showed significant upregulation in Type I samples at <1 year (P=5.4x10-7), 1-2 (P=0.023), 2-3 
(P=0.0064) and >4 years tDx (P=0.00039). In Type II cases it displayed significant upregulation <1 
year tDx. Whilst in the pan OC comparison it demonstrated upregulation <1 (P=8.7x10-12), 1-2 
(P=0.023) and >4 years tDx (P=0.0046). 
Triage:  
Sensitivities for detection of OC using the putative biomarkers were assessed by applying selected 
cutoffs and an ‘OR’ rule (O'Brien et al, 2015) for the expression of each biomarker alone and in 
combination with each other and CA125 (table 1), improvements in sensitivity have been highlighted 
in grey.  
Threshold models demonstrate improved sensitivity for OC  
The selected thresholds were LCAT: <8.831 µg/mL ; SHBG: <16.1 nmol/L  and IGFBP2: >78.5 ng/mL 
set to give a 5% false positive rate. The threshold for CA125 was taken as the level at which a woman 
would be referred to a gynaecological oncologist 35 U/mL (Cramer et al, 2011a).  With a small 
decrease in specificity the combined panels all yielded dramatically increased sensitivity over CA125 
alone for both Type I and Type II OC.  
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Screening:  
The putative biomarkers were again assessed, at yearly intervals, by applying selected cutoffs and an 
‘OR’ rule (O'Brien et al, 2015) for the expression of each biomarker alone and in combination with 
each other and CA125 (supplemental table 3); statistically significant improvements in sensitivity are 
shown in orange.  
Individual models outperform CA125  
Whilst individual threshold models [IGBFP2 / SHBG/  LCAT] displayed increased sensitivity over 
CA125 alone for various time points for Type I, Type II and Pan OC they were not statistically 
significant. 
Individual markers combined with CA125 models outperform CA125 alone 
IGBFP2: CA125 threshold model out performed CA125 (supplemental table 3) in Type I ovarian 
cancer at >4 year tDx where its sensitivity was >5 times that of CA125, however, the specificity was 
slightly lower. For Type II patients it outperformed CA125 at 1-2 years tDx where sensitivity tripled. It 
also outperformed CA125 in terms of sensitivity at >4 years tDx where its sensitivity quadrupled but 
with slightly lower specificity. In the pan OC analysis it outperformed CA125 at <1 and at 1-2 years 
tDx. It also outperformed CA125 in terms of sensitivity at 2-3 and >4 tDx, but with a slight decrease 
in specificity. 
The SHBG: CA125 model did not significantly outperform CA125 (supplemental table 3) in the Type I, 
Type II or pan OC analysis. 
The LCAT: CA125 model only out performed CA125 for pan OC at <1 year tDx.  
Combination biomarker models outperform CA125 alone 
Figure 4 shows the performance, in terms of sensitivity, of the multiple marker combinations in 
conjunction with CA125. The plots demonstrate an improvement in sensitivity for all the 
combination panels compared to CA125 alone for Type I, Type II and Pan OC.  
The SHBG: IGFBP2 :CA125 model most strikingly significantly outperformed CA125 alone  in Type I 
ovarian cancer at <1 and > 4years to diagnosis. Whilst for Type II it significantly outperformed CA125 
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at 1-2 and >4 years tDx. In the pan OC analysis it also outperformed CA125 in terms of sensitivity at 
all times points, with only 3-4 years tDx not displaying significance. 
The LCAT: SHBG: CA125 model significantly outperformed CA125, for Type I at <1 year tDx.  For Type 
II patients it outperformed CA125 at all time points, but with no statistical significance. In the pan OC 
analysis it significantly outperformed CA125 at >4,  1-2 and <1 year to tDx.   
The IGFBP2: LCAT: CA125 model significantly outperformed CA125 in Type I ovarian cancer at >4, 1-2 
and <1 year tDx. For Type II patients it significantly outperformed CA125 at >4 and 1-2 years to tDx. 
In the pan OC analysis it also outperformed CA125 in terms of sensitivity at all times points, with 
only 3-4 years tDx not displaying significance. 
The combination of all markers (LCAT: SHBG: IGFBP2: CA125) model significantly outperformed 
CA125 (Figure 4) in Type I ovarian cancer at >4, 1-2 and <1 years tDx.  For Type II patients it 
significantly outperformed CA125 at >4 and 1-2 years to tDx. In the pan OC analysis it also 
outperformed CA125 in terms of sensitivity at all times points, with only 3-4 years tDx not displaying 
significance. 
Although the all marker combination performs well, its specificity is lowered by the presence of 
SHBG (supplemental table 3). This means that the IGFBP2: LCAT: CA125 model provided the best 
improvement in performance for the detection of OC over CA125 alone. 
Lead time estimation 
For Type I OC 11 women were not detected by either elevated CA125 or the combined IGFBP2: 
LCAT: CA125 model. Of the remaining eight subjects, five were detected earlier by this combined 
model, of which four were not detected by CA125 alone. For the combined model the mean lead 
time was 454 days tDx, whilst for CA125 alone it was 315 days tDx (P=0.032).  
For Type II OC 13 women were not detected either by CA125, or combined IGFBP2: LCAT: CA125 
model. Of the remaining 17 women, four were detected by the combined model earlier than CA125 
alone, and two of these were not detected by the CA125 threshold at all. For this combined model 
the mean lead time was 272 days tDx, whilst for CA125 alone the lead time was 165 days tDx. 
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Combining all OC together, gave a mean lead time for CA125 alone of 213 days and the IGFBP2: 
LCAT: CA125 model of 330 days (P=0.014), a difference of 107 days equating to a four month 
improvement over CA125 alone. 
Prognosis 
An additional question that can be asked is does this IGFBP2: LCAT: CA125 threshold model provide 
us with information on the aggressiveness of the ovarian cancers. This was investigated via Kaplan-
Meier analysis, using the time from diagnosis to death. Plotting survival curves for the Type II 
patients that breach this threshold versus those that do not (figure 5) confirmed a significant 
difference in survival curves; those patients that breach the IGFBP2: LCAT: CA125 threshold model 
(figure 5A) have a lower survival (P=0.047) than those that do not. This is directly attributable to the 
threshold model as figure 5B shows that in survival curves based on CA125 alone there is no 
difference in survival between those who cross the CA125 threshold and those who do not (P=0.254) 
confirming IGFBP2: LCAT: CA125 as a prognostic panel.  
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Discussion 
Despite intensive efforts over the past 3 decades to improve treatment (both surgery and 
chemotherapy) for the disease, there is still a poor outcome for women diagnosed with OC. In 2014, 
7,378 women in the UK were diagnosed with ovarian cancer and there were 4,128 deaths. The 
majority of OC cases are diagnosed at late stage, with a 5 year survival rate of less than 23% for 
Stage III & IV cancers (CRUK, 2014; Hüttenhain et al, 2012; Nolen & Lokshin, 2011). When detected 
early prognosis is much better, with >90% of women diagnosed at Stage I surviving five years (CRUK, 
2014). There is therefore a significant need to develop strategies which can detect OC early. Serum 
biomarkers are attractive targets for early detection and indeed the serum marker CA125 has been 
widely used in screening trials for OC (Bristow et al, 2013; Cramer et al, 2011b; Drescher et al, 2013; 
Menon et al, 2009b; Moore et al, 2009; Skates, 2012). However CA125 has limitations of specificity 
for OC (Jacobs & Bast, 1989b). Thus, there is a real need for the identification and development of 
biomarkers capable of improving on or complementing CA125 in order to enable the earlier 
detection of OC. 
This is the first study to have investigated the expression of putative ovarian cancer biomarkers 
IGFBP2, LCAT, SHBG, GRP 78 and calprotectin in prospectively collected pre-clinical samples, 
enabling an unbiased assessment of how these markers alter during OC progression.  
The most effective biomarker panel was a combination of IGFBP2: LCAT: CA125. This panel identified 
26% of Type I subjects and 13% of Type II subjects not identified by the CA125 threshold alone. This 
panel also displayed an increased lead time of 5-6 months for Type I and 3-4 months for Type II OC. 
It is important to note when considering the above lead time results that women enrolled on the 
UKCTOCS study were on average diagnosed between one and two years earlier than is typical in the 
unscreened population, giving potential lead times of 2-3 years offering a significant window for 
clinical intervention.   
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Kaplan Meyer plots also demonstrate that this threshold panel is discriminatory for more aggressive 
OC as Type II subjects who breach the threshold model have a lower survival rate than Type II 
patients who do not. 
Following initial analysis of IGFBP2, LCAT, SHBG, GRP 78 and calprotectin within our discovery set 
IGFBP2, LCAT and SHBG, were taken forward as potential markers for OC and further analysed within 
our corroboration set. Markers were analysed over a seven years pre-diagnosis period and binned 
into yearly time windows (figure 3). IGFBP2 displayed significant up regulation at <1 year tDx for the 
Type I and Pan OC analysis. Whilst SHBG displayed significant down regulation in Type I, Type II and 
Pan OC at 2-3 years to diagnosis. LCAT showed significant down regulation in Type I OC at <1 year 
tDx and significant upregulation at >4 years tDx. However, none of these markers outperformed 
CA125.  
In order to ascertain if the putative biomarkers could be constructed into a panel with CA125 that 
would improve on CA125 alone, for the early detection of OC, threshold models were investigated. 
These models were constructed for all members of the biomarker panel and combinations tested 
against CA125 alone. The combination of CA125 and IGBP2 improved the sensitivity for detection of 
OC for both Type I and Type II at > 4 years and for Type II at 1-2 pre-diagnosis. The combination of 
CA125 and LCAT showed improvements against CA125 alone in the <1 year time range for Pan OC.  
At the next level CA125 was combined with two markers IGBP2: SHBG, LCAT:SHBG and IGBP2:LCAT. 
The most striking feature of the two panels containing SHBG is that it has a deleterious effect on the 
specificity of the models.  
The most effective biomarker panel was IGFBP2: LCAT: CA125, this panel outperformed CA125 in 
terms of sensitivity at nearly all time points measured for the Type I and Type II cancers. With at 
least a doubling in the sensitivity of the panel at 0-2 years’ pre diagnosis for Type I OC and a greater 
than tripling in sensitivity for Type II at 1-2 and > 4 years tDx. For Type I OC 11 women were not 
detected by elevated CA125 or the combined IGFBP2: LCAT: CA125 threshold. Of the remaining eight 
subjects five were detected earlier by the combined threshold, of which four were not detected by 
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CA125 alone. For the combined threshold the mean lead time was 454 days tDx, whilst for CA125 
alone it was 315 days tDx (P=0.032).  
For Type II OC 13 women were not detected either by CA125, or combined IGFBP2: LCAT: CA125 
thresholds. Of the remaining 17 women, four were detected by the combined threshold earlier than 
CA125 alone, of these two were not detected by the CA125 threshold at all. For the combined 
threshold model the mean lead time was 272 days tDx, whilst for CA125 alone the lead time was 165 
days tDx. Combining all OC together, gave a mean lead time for CA125 alone of 213 days and the 
combined model of 330 days (P=0.014), a difference of 107 days equating to a four month 
improvement over CA125 alone. 
This is the first study to have investigated the expression of putative ovarian cancer biomarkers 
IGFBP2, LCAT and SHBG in prospectively collected pre-clinical samples. Treated as single markers 
these proteins offered low sensitivities, but in a combined threshold model they were able to 
correctly identify OC in samples that did not breach the CA125 threshold, improving on the 
sensitivity of CA125 alone and identifying cases it missed. In addition they provide an increased lead 
time of several months in the detection of OC over CA125 alone and importantly identified the more 
aggressive Type II cancers. Before their utility in a clinical setting can be assessed these panels will 
need to be further validated in larger cohorts. However, the threshold models generated within this 
study demonstrate the potential of these biomarkers in improving the sensitivity and detection of 
OC as part of a panel incorporating CA125. 
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Table 1: 
Performance of threshold models for samples, with no temporal information, for each of the putative biomarkers individually and in combination.  
Thresholds are annotated on the table. Improvements in sensitivity have been highlighted in grey 
 
Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty Sensitivity Spesificty
Type-I 0.09 1 0.09 0.95 0.02 0.95 0.06 0.95 0.18 0.95 0.11 0.95 0.15 0.95 0.20 0.90 0.23 0.90 0.17 0.90 0.25 0.86
Type-II 0.14 1 0.09 0.95 0.02 0.95 0.04 0.95 0.22 0.95 0.16 0.95 0.17 0.95 0.24 0.90 0.24 0.90 0.19 0.90 0.25 0.86
Pan OC 0.12 1 0.09 0.95 0.02 0.95 0.05 0.95 0.20 0.95 0.14 0.95 0.16 0.95 0.22 0.90 0.23 0.90 0.18 0.90 0.25 0.86
AllCA125 | LCAT | SHBGCA125 | LCAT | IGFBP2CA125 | IGFBP2 |SHBPCA125 | LCATLCAT <8.831 µg/mL SHBG : <16.1 nmol/L  CA125 > 35 U/mL IGFBP2 >78.5 ng/mL CA125 | SHBGCA125 | IGFBP2
Titles and legends to figures 
 
Figure 1: Box plot showing putative biomarker expression in the discovery sample set at >32 months 
tDx and <14 months tDx. The whisker limits represent the 5th and 95th percentiles; the box limits 
represent interquartile range; the closest point in the notches (><) of the box plot represents the 
median and the span from the bottom to the top of the notch is 95% confidence interval (for 
significant values between cases and controls it can be seen that these do not overlap). Significant p-
values are indicated on the plot. (For this initial triage the value for IGFBP2 is shown as it is close to 
the cut off) 
 
Figure 2: Comparison of putative biomarker expression in pre-diagnosis sets with no division by time 
to diagnosis. The whisker limits represent the 5th and 95th percentiles; the box limits represent 
interquartile range; the closest point in the notches (><) of the box plot represents the median and 
the span from the bottom to the top of the notch is 95% confidence interval (for significant values 
between cases and controls it can be seen that these do not overlap). Significant p-values are 
indicated on the plot. 
Figure 3: Comparison of putative biomarker expression in pre-diagnosis sets, divided into yearly 
intervals. The whisker limits represent the 5th and 95th percentiles; the box limits represent 
interquartile range; the closest point in the notches (><) of the box plot represents the median and 
the span from the bottom to the top of the notch is 95% confidence interval (for significant values 
between cases and controls it can be seen that these do not overlap). Significant p-values are 
indicated on the plot. 
 
Figure 4: Graph showing the increase in sensitivity, over time, of the combined threshold models 
versus CA125 alone for  Type I OC, Type II OC and Pan OC. Significant p-values are indicated on the 
plot. 
Figure 5:  Survival curves: (A) for the combined threshold model (IGFBP2: LCAT: CA125), (B) for 
CA125, using time to death post diagnosis. The dotted black line represents Type II patients who did 
not breach the threshold. The solid black line represents Type II patients with samples that breached 
the threshold. 
 





